<SEC-DOCUMENT>0001493152-22-014094.txt : 20220517
<SEC-HEADER>0001493152-22-014094.hdr.sgml : 20220517
<ACCEPTANCE-DATETIME>20220517080118
ACCESSION NUMBER:		0001493152-22-014094
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220516
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220517
DATE AS OF CHANGE:		20220517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		22932290

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ABEO="http://abeonatherapeutics.com/20220516">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_ABEO_abeonatherapeutics.com_20220516 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20220516_20220516 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20220516.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-05-16to2022-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-16</xbrli:startDate>
        <xbrli:endDate>2022-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20220516__20220516_zbnqBDF3ovJb"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>PURSUANT
TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Date
of report (Date of earliest event reported): <b><span id="xdx_905_edei--DocumentPeriodEndDate_c20220516__20220516_zfcxzFUd77sb"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 16, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityRegistrantName_c20220516__20220516_zFUkujPW7Jb8"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityRegistrantName">ABEONA
THERAPEUTICS INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20220516__20220516_zPu41aOZzHqk"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityFileNumber_c20220516__20220516_zIf9fyXioQz"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20220516__20220516_z9SQrX7A1Gp8"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">File
Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</span></p>
                                                                             <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></p></td></tr>
  </table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20220516__20220516_zh3x9OT6OSsl"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityAddressAddressLine1">1330
Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressAddressLine2_c20220516__20220516_zqaga2fb5P04"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityAddressAddressLine2">33rd Floor</ix:nonNumeric></span>, </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20220516__20220516_zJFYUE39RYyi"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressStateOrProvince_c20220516__20220516_zkdvYmAugfw1"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20220516__20220516_zZhM3ddupNm3"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric> </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--CityAreaCode_c20220516__20220516_z010eJn7wTB9"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:CityAreaCode">(646)</ix:nonNumeric></span>
<span id="xdx_901_edei--LocalPhoneNumber_c20220516__20220516_zC1WDdo8qlUa"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:LocalPhoneNumber">813-4701</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">N/A</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--WrittenCommunications_c20220516__20220516_zUBbAwZcbOz4"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--SolicitingMaterial_c20220516__20220516_zOSnoDf4kpv2"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--PreCommencementTenderOffer_c20220516__20220516_z6Hd1HMY9rn2"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20220516__20220516_zOgodYcUP2dj"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 44%"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--Security12bTitle_c20220516__20220516_zNnHrPWhxafd"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--TradingSymbol_c20220516__20220516_zo3OiazLc4Zj"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span><span><span id="xdx_90A_edei--SecurityExchangeName_c20220516__20220516_zY0HBrXxEobg"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Markets</span></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20220516__20220516_zhxFmiBk3m39"><ix:nonNumeric contextRef="From2022-05-16to2022-05-16" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
    1.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 16, 2022, Abeona Therapeutics Inc. (the &#8220;Company&#8221;) and Ultragenyx Pharmaceutical Inc. (&#8220;Ultragenyx&#8221;) entered
into an exclusive license agreement (the &#8220;License Agreement&#8221;) for AAV gene therapy ABO-102 for the treatment of Sanfilippo
syndrome type A (MPS IIIA) (&#8220;ABO-102&#8221;). Under the License Agreement, Ultragenyx will assume responsibility for the ABO-102
program, with the exclusive right to develop, manufacture, and commercialize ABO-102 worldwide. Also pursuant to the License Agreement,
following regulatory approval, the Company is eligible to receive tiered royalties from mid-single-digit up to 10% on net sales and up
to $30.0 million in commercial milestone payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
License Agreement is effective as of May 16, 2022 and will continue in full force and effect, on a licensed product-by-licensed product
basis until the end of the royalty term for such licensed product. The royalty term for each licensed product will continue from the
first commercial sale of the licensed product until the later of (i) the date that no valid patent claim would be infringed in the absence
of the license granted under the License Agreement by the sale of the licensed product in the first country in which no such valid patent
claim exists, and (ii) the tenth anniversary of the first commercial sale of the licensed product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
License Agreement may be terminated by (i) either party upon a material breach by the other party (subject to prior written notice and
a cure period), (ii) either party upon certain insolvency events, including bankruptcy proceedings, (iii) by Ultragenyx for convenience
upon six months&#8217; written notice, or (iv) by Ultragenyx upon written notice in the event Ultragenyx makes a good faith determination
that there is a material safety issue or efficacy concern with respect to the licensed products, with Ultragenyx bearing responsibility
for clinical study wind-down in the case of termination while clinical studies are ongoing. The License Agreement includes standard and
customary provisions regarding, among other things, compliance with laws and regulations, confidentiality, intellectual property, representations
and warranties, liability, indemnification, and insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the License Agreement is qualified in its entirety by reference to the complete text of the License Agreement,
which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending June 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
7.01 Regulation FD Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 17, 2022, the Company and Ultragenyx issued a joint press release announcing the License Agreement. A copy of the press release
is attached hereto as exhibit 99.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press release dated May 17, 2022, entitled &#8220;Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics&#8221;</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURE
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Abeona
    Therapeutics Inc. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant)
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Brendan M. O&#8217;Malley </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Brendan
    M. O&#8217;Malley </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Senior
    Vice President, General Counsel </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">Date:
May 17, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUwFjXxMKiKLEIlel5xiSXdkdrP8pP6yVYmGgWHm3jNXiJnY0kbVyHBZFTmU2LS1tAgF3pBRX9E5st0+BTcLvCtjWWo7rj8wI8egY2J/Id19dHbKYJVCEM/DZB5FECRpvITTQXiDnpG+qQq1VbIGqSs4MbWs0Erupw+lfJOmph+TzshGkU4h9INJ/kAUhBEcqZMv4oeBPM+ENxvLE1umZzvEPI2lBtY1Ni7LTOi/vS/l8Ukn -->

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt/106% Times New Roman, Times, Serif; width: 34%"><IMG SRC="ex99-1_01.jpg" ALT="" STYLE="height: 74px; width: 230px"><FONT STYLE="color: #2B579A; background-color: #E6E6E6"></FONT></TD>
    <TD STYLE="font: 11pt/106% Times New Roman, Times, Serif; width: 33%; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 11pt/106% Times New Roman, Times, Serif; width: 33%; text-align: right"><IMG SRC="ex99-1_02.jpg" ALT="" STYLE="height: 91px; width: 240px"><FONT STYLE="color: #2B579A; background-color: #E6E6E6"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ultragenyx
Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ABO-102
/ UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interim
data featured in encore oral presentation at American Society of Gene &amp; Cell Therapy (ASGCT) today</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOVATO,
Calif., NEW YORK, NY and CLEVELAND, OH &mdash; MAY 17, 2022 &mdash; </B>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics
Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo
syndrome type A (MPS IIIA). Under the terms of the agreement, Ultragenyx will assume responsibility for the ABO-102 program and in return
Abeona is eligible to receive tiered royalties of up to 10% on net sales and commercial milestone payments following regulatory approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Based
on promising data from Abeona&rsquo;s clinical program, regulatory feedback to date, and our experience developing treatments for other
MPS diseases, we believe ABO-102 has the potential to be a transformative therapy for patients with MPS IIIA,&rdquo; said Emil D. Kakkis,
M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. &ldquo;Our team&rsquo;s expertise in MPS and gene therapy clinical
development makes this program a seamless integration and it has the potential to be our first gene therapy to market. The Sanfilippo
community has been waiting too long for a first treatment and we believe we can help accelerate this program.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Data
from the ongoing Transpher A trial demonstrate ABO-102 holds significant potential to improve outcomes for patients with MPS IIIA who
experience relentlessly progressing neurodevelopmental and physical decline that is life-threatening at a very young age,&rdquo; said
Vish Seshadri, Ph.D., Chief Executive Officer of Abeona. &ldquo;We believe that Ultragenyx, with deep expertise in rare, genetic, metabolic
lysosomal storage disorders and a demonstrated commitment towards MPS diseases, is the ideal partner to eventually bring ABO-102 to patients.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
has completed a successful Type B meeting with the U.S. Food and Drug Administration (FDA) regarding the pivotal Transpher A trial to
support filing and approval for ABO-102 for the treatment of patients with MPS IIIA. Interim results from the Transpher A trial presented
in an encore presentation at the American Society of Gene &amp; Cell Therapy (ASGCT) today demonstrate that neurocognitive development
was preserved in children treated before 2 years old or development quotient (DQ) &gt; 60 (n=10) within normal range of a non-afflicted
child after treatment with ABO-102 (3x10<SUP>13 </SUP>vg/kg). The interim results also showed continued or stabilized cognitive function
and behavioral progress using standard developmental assessments. Some of these patients have reached 24-months post treatment and stabilization
or increase in cortical gray matter, total cerebral, and amygdala volumes have been observed. Statistically significant reduction in
liver volume was seen with ABO-102 treatment. Dose-dependent and statistically significant reductions in cerebrospinal fluid and plasma
heparan sulfate, demonstrating replacement of enzyme activity consistent with levels required for disease correction in the central nervous
system, have been sustained in treated patients for two years after treatment. ABO-102 has been well-tolerated with no treatment-related
serious adverse events and no clinically meaningful adverse events reported.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;MPS
IIIA is characterized by severe neurodegeneration with debilitating symptoms for which there is currently no treatment,&rdquo; said Kevin
Flanigan, M.D., director of the Center for Gene Therapy at Nationwide Children&rsquo;s Hospital in Columbus, Ohio, and Transpher A study
principal investigator. &ldquo;The promising results to date suggest a single intravenous dose of ABO-102 AAV-based gene therapy has
the potential to help children with MPS IIIA sustain neurocognitive development when they are treated during early stages of their disease.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
ABO-102 / UX111</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABO-102
(now UX111), is a novel gene therapy in Phase 1/2 development for Sanfilippo syndrome type A (MPS IIIA), a rare lysosomal storage disease
with no approved treatment that primarily affects the central nervous system (CNS). ABO-102 is dosed in a one-time intravenous infusion
using a self-complementary AAV9 vector to deliver a functional copy of the SGSH gene to cells of the CNS and peripheral organs. The therapy
is designed to address the underlying SGSH enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain
and throughout the body that results in progressive cell damage and neurodevelopmental and physical decline. The ABO-102 program has
received Regenerative Medicine Advanced Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S., and PRIME
and Orphan medicinal product designations in the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Transpher A Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Transpher A Study (ABT-001) is an ongoing, two-year, open-label, dose-escalation, Phase 1/2 global clinical trial assessing ABO-102 for
the treatment of patients with Sanfilippo syndrome type A (MPS IIIA). The study is intended for patients from birth to 2 years of age,
or patients older than 2 years with a cognitive developmental quotient of 60% or above. ABO-102 gene therapy is delivered using AAV9
technology via a single-dose intravenous infusion. The study primary endpoints are neurodevelopment and safety, with secondary endpoints
including behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, heparan sulfate levels in CSF,
plasma and urine, and brain and liver volume.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further
details can be referenced here: https://clinicaltrials.gov/ct2/show/NCT02716246</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Sanfilippo syndrome type A (MPS IIIA)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanfilippo
syndrome type A (MPS IIIA) is a rare, fatal lysosomal storage disease with no approved treatment that primarily affects the CNS and is
characterized by rapid neurodevelopmental and physical decline, often by age three. MPS IIIA has a global incidence of one in 100,000
with a median life expectancy of 15 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Children
with MPS IIIA present with progressive language and cognitive decline and behavioral abnormalities. Other symptoms include sleep problems
and frequent ear infections. Additionally, distinctive facial features with thick eyebrows or a unibrow, full lips and excessive body
hair for one&rsquo;s age, and liver/spleen enlargement are also present in early childhood. MPS IIIA is caused by genetic mutations that
lead to a deficiency in the SGSH enzyme responsible for breaking down glycosaminoglycans, which accumulate in cells throughout the body
resulting in rapid health decline associated with the disorder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Ultragenyx Pharmaceutical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ultragenyx
is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic
diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with
high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx&rsquo;s
strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients
with the utmost urgency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information on Ultragenyx, please visit the company&rsquo;s website at: www.ultragenyx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Abeona Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona&rsquo;s
lead clinical program is EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa
in Phase 3 development. The Company&rsquo;s development portfolio also features AAV-based gene therapies for ophthalmic diseases with
high unmet medical need. Abeona&rsquo;s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety
of devastating diseases. Abeona&rsquo;s fully integrated gene and cell therapy cGMP manufacturing facility produces EB-101 for the pivotal
Phase 3 VIITAL&trade; study and is capable of clinical and potential commercial production of AAV-based gene therapies. For more information,
visit www.abeonatherapeutics.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ultragenyx
Forward-Looking Statements and Use of Digital Media</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx&rsquo;s
expectations and projections regarding its business plans and objectives, the therapeutic potential and clinical benefits of its products
and product candidates, expectations regarding the safety and tolerability of its products and product candidates, and future clinical
developments or commercial success for its products or product candidates are forward-looking statements within the meaning of the &ldquo;safe
harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial
risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance
or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties
include, among others, the ability of Ultragenyx and its third party partners to successfully develop product candidates, including ABO-102
/ UX111, the effects from the COVID-19 pandemic on the company&rsquo;s clinical and commercial activities and business and operating
results, risks related to reliance on third party partners to conduct certain activities on the company&rsquo;s behalf, the potential
for any license or collaboration agreement, including the company&rsquo;s license agreement with Abeona as described in this press release,
to be terminated, uncertainty and potential delays related to clinical drug development, the company&rsquo;s ability to achieve its projected
development goals in its expected timeframes, risks and uncertainties related to the regulatory approval process, smaller than anticipated
market opportunities for the company&rsquo;s products and product candidates, manufacturing risks, competition from other therapies or
products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations,
the company&rsquo;s future operating results and financial performance, the timing of clinical trial activities and reporting results
from same, and the availability or commercial potential of Ultragenyx&rsquo;s products and drug candidates. Ultragenyx undertakes no
obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx
in general, see Ultragenyx&rsquo;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 5, 2022,
and its subsequent periodic reports filed with the SEC.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>In
addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social
media outlets to publish important information about the company, including information that may be deemed material to investors,
and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely
posted and is accessible on Ultragenyx&rsquo;s investor relations website (https://ir.ultragenyx.com/) and LinkedIn website </I><FONT STYLE="color: #8764B8"><U>(</U></FONT><I>https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/mycompany/).</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted
to identify forward-looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances),
which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited
to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition; continued interest in our rare
disease portfolio; our ability to commercialize our EB-101 product candidate; obtaining a strategic partnership to take over development
activities for ABO-102; our ability to enroll patients in clinical trials; the outcome of any future meetings with the U.S. Food and
Drug Administration or other regulatory agencies; the impact of competition; the ability to secure licenses for any technology that may
be necessary to commercialize our product candidates; the ability to achieve or obtain necessary regulatory approvals; the impact of
changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; reducing our operating
expenses and extending our cash runway; our ability to execute our operating plan and achieve important anticipated milestones; and other
risks disclosed in the Company&rsquo;s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and
Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events
or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise,
except as required by the federal securities laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">###</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Ultragenyx
Pharmaceutical Inc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
Higa</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ir@ultragenyx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeff
Blake</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media@ultragenyx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Abeona
Therapeutics</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors
and Media </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greg
Gin</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ir@abeonatherapeutics.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_01.jpg
<TEXT>
begin 644 ex99-1_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #M MT# 2(  A$! Q$!_\0
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MSWMM =LLT:'T9@*DCE67YDD1E]5.:TWV+4DWHR>D)Q29I#2N4/HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %(K!AD>I'Y4M,B^X?]YOYF@!QZTE*>M-)QT-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY0OW0G##\*TV",",;L^M?/$\-UIEZT,@DAN(S@X./QK3L_&&N6BA8[YV3T<
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M4L1"I\)N"E/2FJ<D^U.ZUDC<ADE6*-G<[549)S7SOXT\1/XBUZ29&_T:,F.
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MXG\47&G7<6G:=")KV3IGH*ZX]:\[DQ)\5P&&0J#'_?%$V^@5I-)>8\#QU/\
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H)@4M% !BDP*6B@ HHHH *0@&EHH ,"C HHH 3 H"A1@=.M+10!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_02.jpg
<TEXT>
begin 644 ex99-1_02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ L0# 2(  A$! Q$!_\0
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M -_]!1]KG_O_ *"H:* )OM<_]_\ 04?:Y_[_ .@J&B@";[7/_?\ T%'VN?\
MO_H*AHH F^US_P!_]!1]KG_O_H*AHH F^US_ -_]!1]KG_O_ *"H:* )OM<_
M]_\ 04?:Y_[_ .@J&B@";[7/_?\ T%'VN?\ O_H*AHH F^US_P!_]!1]KG_O
M_H*AHH F^US_ -_]!1]KG_O_ *"H:* )OM<_]_\ 04?:Y_[_ .@J&B@";[7/
M_?\ T%'VN?\ O_H*AHH F^US_P!_]!1]KG_O_H*AHH F^US_ -_]!1]KG_O_
M *"H:* )OM<_]_\ 04?:Y_[_ .@J&B@";[7/_?\ T%'VN?\ O_H*AHH F^US
M_P!_]!1]KG_O_H*AHH F^US_ -_]!1]KG_O_ *"H:* )OM<_]_\ 04?:Y_[_
M .@J&B@";[7/_?\ T%'VN?\ O_H*AHH F^US_P!_]!1]KG_O_H*AHH F^US_
M -_]!1]KG_O_ *"H:* )OM<_]_\ 04?:Y_[_ .@J&B@";[7/_?\ T%'VN?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8C\YZGTKWL1B(8>FZD]D0.OM46 F.+#2=SV%8DL\D[;I&+&H^2>Y)K7L=)#
M27&?9/\ &OE93Q69U.6.W;HO4O1&4B/(<(C,?858&GW1'^I;\:Z1(TC7:BA1
MZ 4ZO0I\/TTO?F[^0<YR[65R@R8'Q["H""IP00?>NOJ*:WBG7$B!O?'-35X?
MC;]U/7S_ . '.<S#<RV[;HV(]JW;'44NAL;Y9/3UK-OM-:VS)'EH_P!16>K%
M6#*2".AK@HXC$Y=5Y)[=NGR!ZG8452TZ]^UPX8_O%Z^_O5VOK:-:%:"J0V9!
M!>_\>,_^X:Y:NHOO^/&?_<-<M7S>?J]6'I^I<6:_]I"WL8HHL&3;R?2LR25Y
M6+2,6/O3%!=@J@DG@"MRSTE$4/<#<W]WL*Y81Q68M07PQLO)?YL+I&*J.YPJ
MD_04\VTX&3$^/]VNJ5%0850H] *6O1CP]"WO3U] YSD""IP01]13HY7B8,C%
M2/2NJDBCE7;(BL/<5C:AI@A4S0YV#JOI7'BLGJX=>TIRNE\F',6K#4Q.1%-@
M/V/K6E7'@D$$'!%=-I]S]JM58GYQ\K?6O2RG,)5OW-5^\MGW$T4=:@P4G _V
M362&*L&'!!R*ZBZA%Q;21GJ1Q]:Y4@J2#U%>9G6&]GB/:QVE^:*B]#J[>83P
M)(/XA4M9&BSY5X">G(K7KZ7!5_;T(U.O7U(84445U""BBJM_/]GM';^(\"HJ
MU%3@YRV0&)J%QY]VQ'W5X%-LH/M%TB8XSD_2JV<GK6YHUOLA:8CEN!]*^,PE
M)XW&7GU=W_7X&C=D+JUIOC\Y!\RCD#N*Q%<JP93@@Y%=<0",'H:YO4;0VMQP
M/W;\K_A7?G6!Y9?6:?S]>XHOH;=E="ZMPW\0X859KF;"[-K< D_(W#"NE!#
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M_KL*]ZK3&_$C;,/C7H%%%%<9P'@_B _\5!??]=FKL/A?_K[[_='\ZXSQ"?\
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M04445L 4444 <]KO_'XG^[4&D'_B8Q_C4VO?\?B?[E0:0?\ B8Q_C7RM5?\
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MU+7F/P^\61VX72+Z0*A/[AV/ _V37IU<%6FZ<K,\ZM2=.7*PHHHK,R"BBB@
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M"CVKBQN,6&CIJWT)E*QT_P!OM/\ GNGYU8!# $'(-<CIMH;R[5<?(O+&NN
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M'Y%/S+7/1RM%(LB'#*<BNU=0Z%6&01@UR&HVC65T4_@/*GVKS,VP\HS5>/\
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M4^G?]=A7T!7S]X6/_%4:=_UV%?0-:X[XD:XWXD%%%%<1Q'S[XC/_ !4>H?\
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MIJ-T1*7+J=:LB.<*ZL?8YH=$D7:ZAAZ$9KCK*\:TNDER2.A'M7812I-&LD;
MJPR#2P>,CB8NZLUT%&7,5)-(LI#GRMI_V3BH3H%IG[TOYC_"M2BM982A)W<%
M]Q7*C-30[)#DJ[?[S5>BMX8!B*-5^@J2BKIT*5/X(I DD%<OK=R)[W8I^6,8
M_&M;5-22SB*(09F' ]/>N5+9))Y)KR<UQ*:]C'YF=270O:5"9M0C'9?F-==6
M/H-H8X&N'&&D^[]*V*ZLLHNE0N]WJ5!604445Z)84A4,,, 0>QI:* *,VD64
MQR80I]5.*JMX<M2>))1^(_PK8HKGEA:$]7%$N$7T,=?#EH#S)*?Q'^%6X-)L
MH#E803ZMS5VBG#"T8:QB@4(KH   P!@4445N4%%%% ",JNI5@"IX(-0?8;7_
M )]X_P#OD58HJ7&+W0K(155%"J %'0"EHHJAA1110 4444 0S6EO.P:6)78<
M9--CLK:%P\<*JPZ$58HJ/9PO>RN*R"BBBK&%(Q"J6/0#)I:S=:NOL]B5!P\G
MRCZ=ZSJU%3@YOH)NRN<]?7'VF\DD[$X'TJ_H-MYMR9V'RQ]/K6-78Z9;?9;)
M$(^8C+?6OGLOI.OB/:2Z:_,QA[TKERBBH+RX%M:22GJ!Q]:^CE)1BY/9&YAZ
MY>>;.+=3\J=?<U5TZR-Y<A3_ *M>6-5"6EDSR68_F:ZW3K,6=JJ?QGEC[U\Y
MAZ;QN)=2?PK^DC)>\RTJA5"J, # %+117TIJ%%%% !1110 UT612KJ&4]014
M/V&U_P"?>/\ [Y%6**EQB]T*R(1:6X&!"@'THJ:BCDCV"R+-]_KU_P!W^IJM
M5F^_UZ_[O]35:J&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U.P%]!@<2+RI
MJ]145*<:D7"6S$U=69PDD;Q2-'(NUE."#5JQU*>Q;"G<AZJ:Z6]TZ"^7YQAQ
MT<=:YZZT6ZMR2J^8GJM?/5<%7PT^>EJNZ_4YY0E%W1LP:[:2@;R8V]ZM#4K(
MC/VF+_OH5QC(RG#*1]13<UI'-:T5:23#VSZG8R:O91C_ %ZM_N\UF7?B!G4I
M;)MS_$>M8-316L\[8CB9C]*B>8XBK[L=/0'5D]ACNTC%G;+'J35_2]->\E#N
M,0J>3Z^U7;+P^20]TW']Q:WD18T"(H51P !6N$RV4I<];;MW*A3;UD*JA5"J
M, # %+117O&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG]*37AG32?1A4FC?\@J'\?YUYZ7^W-_W3/[9?HHHKT#0**** "BBB@ HHHH
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2N?J: ,RBM/[)!_<_4T4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>abeo-20220516.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeOybP9z5Z8CekhvWB0banK/ygnsXyqiyi7+UUWwWUK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:ABEO="http://abeonatherapeutics.com/20220516" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics.com/20220516">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20220516_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20220516_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>abeo-20220516_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>abeo-20220516_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20220516.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140222049442744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 16,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA
THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1330
Avenue of the Americas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">33rd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abeo-20220516.xsd" xlink:type="simple"/>
    <context id="From2022-05-16to2022-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-05-16to2022-05-16">0000318306</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-05-16to2022-05-16">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-05-16to2022-05-16">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-05-16to2022-05-16">2022-05-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-05-16to2022-05-16">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-05-16to2022-05-16">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-05-16to2022-05-16">001-15771</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-05-16to2022-05-16">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-05-16to2022-05-16">1330 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-05-16to2022-05-16">33rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-05-16to2022-05-16">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-05-16to2022-05-16">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-05-16to2022-05-16">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-05-16to2022-05-16">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-05-16to2022-05-16">813-4701</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-05-16to2022-05-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-05-16to2022-05-16">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-05-16to2022-05-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-05-16to2022-05-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-05-16to2022-05-16">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-05-16to2022-05-16">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-05-16to2022-05-16">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-05-16to2022-05-16">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP<7AFC-X">P-\/M2*?-V8C?#Y?\R!O\ 4$L#!!0    ( "- L52?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( "- L50'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ (T"Q5+P:
M5]+N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ (T"Q5)E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  C0+%41 9^EU $  #7
M$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ (T"Q5)^@&_"Q @  X@P   T              ( !DPP
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  C0+%4EXJ[',     3 @  "P
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52P4&      D "0 ^ @  YQ,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>abeo-20220516.xsd</File>
    <File>abeo-20220516_lab.xml</File>
    <File>abeo-20220516_pre.xml</File>
    <File>ex99-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20220516_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20220516_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abeo-20220516.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABEO",
   "nsuri": "http://abeonatherapeutics.com/20220516",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-05-16to2022-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abeonatherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-05-16to2022-05-16",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-22-014094-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-014094-xbrl.zip
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MO1 +![4$8LK%-[**!"F:,O-EP.&+-Q<_>U["FX977I7(0)^+3[!#A*AXT>1
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M:RXF\LH^^.%_F;KOOOMN4TG;;,8A@#DDQSG:[# %\6\SF[JV'__#QE*_X2)
MC-M<YD%"3T*BB/X5OLT5TO\V=E;*;N=GV+9-I5'G_]5.26TJH1NN,P>ON/5J
MPP523> Z'R1PNS:51.;B/1%) .6Z;N)-!L^-UZ(&M%/TP>)PY__DV5W2_ ;A
M:K?S1F>;2B 0?GU_[J82?,,]J+?5;W_8$V?<%&!?BE.Z-NRAG/N%<N[#J>!O
M0-TV_4O0[I^&IG]!^O\ 4$L#!!0    ( "- L53?3)8981<  &N;   +
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M%1ZR@IK+'BFNO><P-_*K _#"*\'NN(2.H)6H8V+5B)KJPE8$%:\$MJBPI-Y
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MZFH70*NH&P<YLZ)A9D.(KJ560*L\1!0;8)#L</S0#Q63 P6/(>6;,+^,, ]
M<CM,20->]@X$!Q9!'F5<960]*D!8 D\)ZG@O+ 8WP ,A-[FQEJLRZ'P'T495
M[@D.\G6OMZQCDH5KZ<^L4&*"I0J3*FOKFEGF9S3!^:9X_9X#T>8=,/U(W[<I
MXV?7.M2Y$8'GPTO@%9,Q?"K5F# H@!@SP#I]X\ 87(N0FD;R(5&78\KPM-P,
MS.N8VEGE=[.CJ<XSZ(7"HZ\%C;4=T!NT9:3G8A:)HDVW6$1UCN5*I0N0 DSE
MO2?$EK3+?#2N,E!'KQB>NJ6 +F "%'*TAX#^1$CW)/F1H2,1 ZG#J-!F/>Z)
MH,$'(MG<4?Z;] -K!%T=*V>Y]TZ$GTFE%M4)!J@?,,2+]T1C3P76RGLN3*4U
M<()%48L);:,4F>82$U@>6%F,XB>.P F!!C 8J!E8M%[(?7Y?K[I*SG'\]I;&
MUZ;WVH4(G1<< UN!PZ?NYJ"(\[HZ.65C-C# G=["!<[$QX)Y0!UHISMBZA%L
M&Q6H:3D*%TRER:8RCVS@C"_[T%H0.#<0",V;_EH(8:Y+P7D;[?YJZ+E\CU)I
MF%]1S 7R)$W!O?B!MD3GY1;6>.IF3^0#@2(&XCW^LDPD2(JA&-IJ_([,HG'!
M3];F4?D-'77&#B:@NH U[(-PC44S%D#AR5SR.5 7B]HC<J%O&0;XU>$^HYC[
M/ X,;G4K='L0V8\!>+KEHG:YWI@KK=3)%NX3N1BK"G)\1(ZX-&T7OY22?_EC
MNJ^9U$^6XW$B8BM*1,2#RIG\@C*#(%GD.PB]3U _HU&P&5HD\#+!7\7T8K*8
M0M@+ NV-7="IWID5M+N^#YX-3("&&#,2<BR^.SMYXTW2TG!#(:2)OO2(.AA%
MCRC)B\KFM4 (U-8S"A%/.R,[U&,K,K=BLD]!!6-)#]2PA>MN13DCI93#M(WV
M<[Q >*YD*H@=%^"V'UCV7U?Z?:!KA?'<5+QQE"5:']^1>,^!)4,W6:4UM+^F
M'0FN85'.H-0 K0,R(D2+Q[&:W%ZHW?:)[0*BHNB$![T7G@$--T6 \9H@HN"<
M+3VN8_*)>;X6!R4U>*:<^6B>?!4(A/=EF]-0J%"1AH#\/<*S!Q&!>=,3H @L
MK 6X8A==4Y\ME52E+?EC"[:#<G0\KC^KZY54.BPN.?)_U)2E#>.JM999B=%T
MJ>ORK[,$]^MC%9WG[!M/+!1/%>F>5>;2K*$Q.'/3+,C- JZI$8/=> ;HC]^\
MG_XBI*P=CR;189J7/#^K&)Q87%Z&+<3)S+6<L*7.+//0_A8,@L[R&WN\2 "[
M3XG^DC$;[NSDC'S?'ZACM+'(U%).^G24J[[Z:T_"DUB46S5O XZ?LGYONQUP
MXRZPXBLQ@X25;;QP*:S23U>V)X5LTHKJV.VY.K:J9B74^L-09;] ?S_U:!0K
M;\R?PN5D[AU>"X8 JMUF#=R^074I^(CZE. =Z625#3K,PJ@8<_!AR:#AX*UW
MY.OAQ0FQP@^.O?@!\)>_?O#G^RI+;_LJW_95IO21Y<0ORBSC99'X:<K&^[-J
M^_*BCI_[3A_<WSJI<!YNRAKG!@53SH#.XCPT-9EPW,$*[!$Q:8!E895F#;]J
M"=-T&)$ /+QP=4VLP_K4[I+.2-]$J5*(80O,LP:X6T^-1P._[PK0%M9;_N,U
M;$%^$4<%L,3'[[*E1Q/PR?!H!U;#,+]C=5F/XO\VY(_=,;T60K*D)!^+Z,8S
M;N5(U4V/X%DN<"JIPK-<')!X]<ER4#]=T Y'NX])VS[CSI6GNX?\H" +&K)#
MP1P+!CG-DV:X(>:4VC8;@3;AJ64A7H42_[M@P(L0?LXC+PY"N.IZXJ2E?UOV
MU&%0E^/LSEOJ?^"&7>9P-TPB_85[9C%3JG9CKH^ODL?/"4MF+V"%W_2NC6>
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MKE6PMR]OG&B-_Q]02P$"% ,4    "  C0+%4NOB>[T(#   3#   $0
M        @ $     86)E;RTR,#(R,#4Q-BYX<V102P$"% ,4    "  C0+%4
M?@=B4_\*  !LAP  %0              @ %Q P  86)E;RTR,#(R,#4Q-E]L
M86(N>&UL4$L! A0#%     @ (T"Q5"X-YM9;!P  U5@  !4
M ( !HPX  &%B96\M,C R,C U,39?<')E+GAM;%!+ 0(4 Q0    ( "- L52E
MD/&N.AH  $AZ   *              "  3$6  !E>#DY+3$N:'1M4$L! A0#
M%     @ (T"Q5-],EAEA%P  :YL   L              ( !DS   &9O<FTX
<+6LN:'1M4$L%!@     %  4 -@$  !U(      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
